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Multidrug transporters are important and interesting molecular machines that extrude a wide 
variety of cytotoxic drugs from target cells. This review summarizes novel insights in the 
energetics and mechanisms of bacterial ATP-binding cassette multidrug transporters as well as 
recent advances connecting multidrug transport to ion and lipid translocation processes in other 
membrane proteins.  
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With contributions from biochemistry, biophysics, cell biology, chemistry, genetics, 
microbiology, oncology, pathology, pharmacology, pharmacy, physiology and structural 
biology (in alphabetical order) and close to 500,000 published research papers in PubMed since 
the first publication on penicillin resistance in 1940 [1], drug resistance is one of the largest, 
most interesting and relevant areas of research of this era. Antibiotics and cytotoxic anticancer 
drugs transformed human and veterinary medicine, but we have reached a point where there 
are hardly any treatment alternatives left for some drug-resistant bacterial infections and where 
50% of cancers develop some form of drug resistance during treatment [2-4]. Cytotoxic drugs 
act by exerting toxic actions within the cell. One important mechanism of drug resistance is 
therefore based on the extrusion of cytotoxic agents by multidrug transporters from the cellular 
interior to the external environment. Due to this extrusion, the cytoplasmic drug concentration 
is lowered to subtoxic levels, allowing the cell to overcome drug toxicity. In the sections below, 
we will summarize basic properties of ATP-binding cassette (ABC) multidrug transporters and 
their sources of metabolic energy with emphasis on, but not restricted to, bacterial 
homodimeric proteins. Recent data will be discussed that narrow the apparent gap between 
ABC multidrug transporters and classes of ion-coupled multidrug transporters. To facilitate 
this discussion, we will start with a brief introduction into bacterial bioenergetics. 
 
Bacterial bioenergetics 
The nutrient and energy demands of microorganisms are frequently not fully met in natural 
habitats. Although some solutes are readily available to living cells in the aqueous 
environment, many other nutrients are very scarce and not easily obtained. Moreover, 
microorganisms are exposed not only to changes in chemical gradients of nutrients but also to 
fluctuations in temperature, pH, redox potential and osmolality. In contrast to the ever changing 
outside world, the chemical and physical composition of the interior of microorganisms is 
much more constant to optimally support the biological processes and metabolic pathways 
underlying DNA replication and cell proliferation. Cells are able to maintain this difference 
between internal and external environments due to the presence of a phospholipid bilayer, 
referred to as the cytoplasmic membrane, which provides a barrier that slows down the rapid 
diffusion of solutes and ions. The cytoplasmic membrane contains channels and transport 
proteins that facilitate the uptake of nutrients and ions required for growth and metabolism at 
physiological rates exceeding the rates of diffusion. Membrane proteins also facilitate the 
efflux of end products of metabolism and of cytotoxic agents encountered in the environment. 
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In bacteria, metabolic energy transducing processes in the cytoplasmic membrane lead to the 
generation of ion motive force and the formation of ATP.  
 Membrane transport proteins belong to a limited number of protein families. They can 
generally be classified into primary-active transport systems that utilize phosphate-bond 
energy in the form of nucleotides to drive substrate transport against a concentration gradient, 
and secondary-active transporters that transduce one form of electrochemical energy into 
another form [5]. Energetically, the most-important electrochemical ion gradient across the 
cytoplasmic membrane in many bacteria is that of protons [6, 7]. Redox-driven proton pumps 
in respiratory chains in aerobic bacteria and the H+-ATPases in (facultative) anaerobic bacteria 
generate these electrochemical proton gradients. The outwardly-directed translocation of 
protons and their positive charge results in the generation of two components: a chemical 
proton gradient (DpH, inside alkaline versus outside acidic) and a membrane potential (Dy, 
interior negative). These components impose an inwardly-directed force on the protons referred 
to as the proton motive force (Dp) that equals: Dy - ZDpH mV, in which Z equals 2.3RT/F 
(where R is the gas constant, T the absolute temperature and F the Faraday constant). 
Secondary-active membrane transporters transduce the metabolic energy contained in the Dp 
into (electro)chemical energy of substrates by mediating the influx of protons across the 
cytoplasmic membrane in co-transport (symport) or counter transport (antiport) with 
substrates. The metabolic energy released during this movement of protons is captured in the 
transporters and used to drive the transport of substrates against their concentration gradients. 
Although proton cycling plays a central role in energy transduction in many living cells, 
sodium cycling is also frequently observed, particularly across cytoplasmic membranes in 
thermophilic bacteria, eukaryotic microorganisms and mammalian cells. The sodium motive 
force (DpNa, interior negative and low) is defined in an analogous way to the Dp, and often 
coexists with the Dp in mesophilic bacteria. 
 
Families of multidrug transporters  
An interesting class of membrane transporters is that of the multidrug transporters. Some of 
the best-studied systems are ATP-binding cassette (ABC) transporters that utilize ATP binding 
and hydrolysis as a source of metabolic energy in the drug translocation process. Other 
multidrug transporters are member of the Major Facilitator Superfamily (MFS), Multiple 
Antibiotic and Toxin Extrusion (MATE) family, Proteobacterial Antimicrobial Compound 
Efflux (PACE) family, or Resistance-Nodulation-cell Division (RND), and are ion-coupled 
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transporters that are dependent on electrochemical ion gradients [8]. While the majority of 
membrane transporters exhibit a selectivity for one substrate or class of substrates, multidrug 
transporters have the ability to transport a very wide range of structurally dissimilar substrates. 
These substrates often have amphiphilic properties allowing their adsorption onto membrane-
water interfaces, from where they diffuse across cytoplasmic membranes into the interior of 
cells. This is particularly relevant for many therapeutic drugs including antibiotics and 
cytotoxic anticancer drugs that accumulate at the inner membrane leaflet of the cytoplasmic 
membrane by Dy (interior negative)-driven passive uptake of the permanent cation or 
protonated weak base, or by DpH (interior alkaline)-dependent trapping of the weak acid 
following its deprotonation in the cellular interior. Many multidrug transporters belonging to 
ABC and MFS families, and possibly also the MATE and PACE families, have the ability to 
transport amphiphilic drugs from the inner membrane leaflet into the compartment that is 
external to the cytoplasmic membrane. In Gram-negative bacteria, this compartment is a gel-
like matrix (referred to as periplasm) that is separated from the extracellular environment by 
the outer membrane. Due to the presence of lipopolysaccharides in its outer leaflet, the outer 
membrane provides another permeability barrier that slows down the diffusion of amphiphilic 
antibiotics into the cell. The transporters in the ABC, MFS, MATE and PACE families 
therefore act in conjunction with multidrug tripartite transporters of the RND family, which 
can transport drugs from the outer leaflet of the cytoplasmic membrane and periplasm across 
the outer membrane to the extracellular environment. In this way, drug transport across the 
cytoplasmic membrane and outer membrane are part of the same drug elimination pathways 
[9]. The phenomenon of drug elimination pathways is also encountered in mammals. Here, the 
ABC multidrug transporters ABCB1 and ABCG2 (also referred to as multidrug resistance P-
glycoprotein and breast cancer resistance protein, respectively) for amphiphilic compounds and 
the ABC multidrug transporters ABCC1 and ABCC2 (also referred to multidrug resistance-
associated protein 1 and 2) for sulfate, glucuronide and glutathione conjugates produced in 
phase I and II drug metabolism, work together to direct incoming amphiphilic drugs in the gut 
and other locations towards their excretion by the liver and kidney [10]. In summary, cells 
generate drug permeability barriers that limit drug diffusion into the cell, and they express 
multidrug transporters that catalyse drug efflux across these barriers at rates that outcompete 
the rates of diffusive uptake. This ingenious system allows the cell to effectively eliminate 
drugs from the interior. In the repertoire of available drug resistance mechanisms in 
microorganisms, drug efflux is therefore an important intrinsic first-line of defence of cells 
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against cytotoxic drugs due to the expression of multidrug transporters at basal levels in 
unchallenged cells. 
 
Mechanisms of ABC multidrug transporters 
Genetic and structural analyses revealed a common architecture of ABC multidrug transporters 
comprising two highly conserved cytosolic nucleotide-binding domains (NBDs) and two 
distinct and evolutionary unrelated a-helical membrane domains (MDs) that constitute the 
substrate-binding chamber and form the transmembrane drug translocation pore [8, 11]. In 
homodimeric ABC transporters, both NBDs are able to hydrolyse the nucleotide, whereas in 
heterodimeric ABC transporters usually only one of the ATP-binding sites has the consensus 
sequences necessary for hydrolytic activity. For most ABC transporters, the bound nucleotide 
is ATP but there are multidrug transporters that prefer GTP over ATP [12]. Resolved crystal 
structures [13-15] and cryo-EM structures [16, 17] for homodimeric MsbA, Sav1866 and 
others (reviewed in [18-21]) provided a significant advancement in our understanding of how 
multidrug ABC transporters mediate their transport activity. These structures have shown the 
relevance of basic “alternating access” models in which the transporter cycles between inward-
facing and outward-facing states in response to nucleotide binding and hydrolysis. It is often 
thought that all protein structures generated by crystallography or cryo-EM fit into a generic 
transport cycle of ABC exporters, and that those that do not fit should be excluded as detergent 
artefacts. However, even within the class of homodimeric ABC exporters it is very likely that 
some conformations are only relevant for a subset of transporters, and hence, that transport 
cycles can differ in the details of transitions [22].  
 Many studies report on substrate-stimulated ATPase activities for ABC transporters 
[23]. Recent advances have shed some light on the question of how ATP binding and substrate 
binding are linked. Studies on MsbA based on cysteine cross-linking, fluorescence energy 
transfer, and cysteine accessibility indicate that the binding of drugs or the physiological 
substrate Lipid A stimulates the maximum rate of ATP hydrolysis by facilitating the 
dimerization of nucleotide-binding domains, thus leading to protein conformations that 
promote ATP binding and occlude the transport substrate [24, 25]. Investigations on the 
mammalian MsbA homologue ABCB1 suggest that ATP binding is also followed by ATP 
occlusion in the NBDs to enable hydrolysis of nucleotide [18, 26, 27] at alternate nucleotide 
binding sites by structurally asymmetric NBDs [28]. This is further supported by early 
biochemical observations on the existence of an ATP plus ADP-bound NBD dimer and the 
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alternating hydrolysis of ATP at the two nucleotide-binding sites [29]. Most recently, the 
substrate-induced acceleration of ATP hydrolysis in ABCB1 was found to correlate with the 
stabilization of a high-energy, post-ATP hydrolysis state characterized by structurally 
asymmetric nucleotide-binding sites [30]. It is still unclear whether the MsbA dimer hydrolyses 
the two ATP molecules in a random, sequential or alternating fashion. However, for each of 
these possible mechanisms, asymmetry would develop following the hydrolysis of the first 
ATP. The in vitro selection of designed ankyrin repeat proteins (DARPin) through their 
specific binding to detergent-solubilized ABC proteins [31] detected asymmetry in the MDs of 
the MsbA dimer [32]. This asymmetry has not yet been captured in protein crystals or recent 
cryo-EM structures, and it is therefore not known whether this asymmetry also extends to the 
NBD dimer.  
 Structural data indicate that the conformational power delivered by ATP binding and 
hydrolysis at the NBDs is transmitted to facilitate substrate binding and translocation by the 
MDs [21]. This is achieved by intracellular loops in the MDs, referred to as coupling helices, 
that interact with the NBDs. Whereas coupling helix 1 (CH1 connecting TM1 and 3) contacts 
the NBDs in both half-transporters, CH2 (connecting TM4 and 5) only interacts with the NBD 
of the opposite half-transporter. These arrangements are different from those in ABC importers 
and the ABC engine MacB of the tripartite macrolide efflux pump MacAB-TolC, where the 
MD only contacts the NBD within the same half-transporter [33]. To enable these interactions 
the NBDs expose short sequence motifs, the Q-loop (in E. coli MsbA 424-QNVHLFNDT) and 
X-loop (in E. coli MsbA 473-VIGENGVLL preceding the ABC signature motif), of which the 
latter is conserved in ABC exporters only. Substitutions of the conserved glutamine residue in 
the two Q-loops in ABCB1 gave rise to a mutant transporter that is trapped in the inward-open 
state; the mutant binds drug but cannot couple to the ATPase cycle [34]. In the human 
phosphatidylcholine ABC transporter ABCB4, a substitution of the conserved glutamine 
residue in the second X-loop is associated with progressive familial intrahepatic cholestasis 
type 3 (PFIC-3) in patients with liver disease; the mutation abrogates substrate-stimulated 
ATPase activity [35]. Recent studies in the MsbA homologue BmrA from Bacillus subtilis 
have shown that, upon ATP-vanadate trapping, substitutions of the conserved glutamate 
residue in the X-loop impair the transition to the outward facing state [36]. Thus, mutations of 
conserved residues at the transmission interface between NBDs and MDs often lead to partial 
or complete inactivation of transport activity. In the absence of a sufficient number of identified 
intermediates, the currently available protein structures do not yet provide a complete picture 
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of the intricate inter- and intra-molecular movements that couple metabolic energy to the efflux 
of drugs. 
 MDs of ABC transporters show little sequence conservation, which is thought to 
support the notion that different members of the ABC superfamily recognize and translocate 
different substrates [37]. However, the lack of sequence similarity is also observed among ABC 
multidrug transporters with overlapping multidrug recognition capabilities, or when ABC 
multidrug transporters are compared to ion-coupled multidrug transporters with a similar drug 
selectivity. This implies that the binding of drugs by reversible weak interactions can be 
achieved through contributions of different subsets of side chains in drug binding pockets. 
Structural analysis of drug-bound transcriptional regulators [38, 39], RND systems [40, 41], 
ABCB1 [42, 43] and ABCC1 [44] confirm this conclusion. Equilibrium vinblastine binding 
data for the MsbA homologue LmrA from Lactococcus lactis demonstrated for the first time 
the binding of two vinblastine molecules with high and low affinity [45]. This protein-drug 
ratio is also observed in cryo-EM structures of MsbA in which two quinolone inhibitor G907 
molecules are bound in architecturally-conserved side pockets that accompany the central 
binding chamber [17]. Moreover, crystal structures of mouse ABCB1a exhibit the binding of 
two molecules of the cyclic peptide inhibitor QZ59-SSS in the central binding chamber [42], 
and analogous cryo-EM studies with a hybrid construct of human and mouse ABCB1 
demonstrate the binding of two molecules of the inhibitor zosuquidar in this location [43]. 
Careful biochemical equilibrium binding experiments, however, indicated single binding sites 
for zosuquidar in human ABCB1 [46] and vinblastine in Chinese hamster ABCB1 [47], and 
suggested complex allosteric interactions between multiple drug interaction sites through 
which the interaction of drug at one site can switch other sites between high- or low-affinity 
conformations [47]. As ligand concentrations were at least 100-fold higher in the structural 
studies compared to the equilibrium binding studies, it is conceivable that the presence of a 
second zosuquidar molecule in ABCB1 remained undetected in the binding experiments if this 
binding event would occur with a low affinity that is too close to non-specific binding. 
However, dissimilarities in experimental outcomes could also be due to other major differences 
in the experimental conditions and sources of ABCB1 protein. The structural data raise the 
question of how the binding of non-transported inhibitors and transported substrates can have 
different outcomes on the activity of ABC transporters when these ligands bind in similar 
pockets and share similar weak drug-protein interactions. 
 Another feature of most MDs in ABC transporters is the presence of the amphipathic 
N-terminal elbow helix that runs parallel to the inside surface of the membrane. By analogy to 
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the peripheral stalk in rotary ATPases that counteract the rotation tendency of the catalytic core 
in response to the movement of the rotor [48], the elbow helix might firmly associate ABC 
exporters to the plane of the membrane and counteract rotational movement perpendicular to 
the membrane. Furthermore, the elbow helix might ensure proper alignment of transmembrane 
helix (TM) 1 with other TMs in the MD in the outward-facing state in which TM1 and TM3 
define the extent of the external opening of the central drug binding pocket towards the external 
environment [49]. TM1 also contains residues important for regulating the gating of the central 
drug binding pocket towards the exterior in the inward-facing conformation [50]. Consistent 
with the importance of the elbow helix, mutant proteins of LmrA with lysine to glutamate 
substitutions in this helix are properly expressed but have strongly reduced transport activities 
[51].  
 
Ion transport reactions 
Most investigations on transport mechanisms of multidrug transporters have been done from 
the perspective that ABC transporters have conserved energetic requirements that are distinct 
from those of secondary-active transporters. The experimental approaches for each of the 
classes is therefore usually dictated by what is custom in the field. However, interesting 
observations are made when tools and techniques used in studies of secondary-active 
transporters are applied to ABC transporters. Reversible substrate transport is a distinct 
property of secondary-active transporters, and occurs when electrochemical ion gradients 
driving substrate transport are dissipated. The transport direction is then dictated by the 
prevailing substrate concentration gradient. One of the consequences of the dissipation of the 
ion motive force in fermentative bacteria is that ion-translocating ATPases that generate the 
ion motive force will consume the available Mg-ATP in an attempt to compensate for the loss 
of ion motive force. In lactococcal cells with a 1000-fold reduction in Mg-ATP concentrations 
to lower µM levels, ABC exporters such as LmrA, MsbA, and Sav1866 [52-54] exhibit 
reversibility in drug transport suggesting that the substrate translocation pathway in their MDs 
is intrinsically reversible. The unidirectionality of these ABC exporters under physiological 
conditions is therefore at least in part imposed by the exothermic nature of the ATP hydrolysis 
reaction causing it to be strongly shifted to the ADP + Pi side. More recently, reversibility in 
transport was reported for the ABC peptide transporter ABCB2/3 (also referred to as TAP1/2) 
following the substitution of the conserved aspartate in the NBDs in the D-loop that coordinates 
NBD dimerization [55]. The reversibility of substrate translocation pathways offers the 
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promise that drug efflux pumps can be utilised for inhibitor-induced drug accumulation in 
target cells. 
Transport studies with ethidium, erythromycin and chloramphenicol in intact cells and 
proteoliposomes prepared from Escherichia coli phospholipids and egg yolk PC established 
that ATP-dependent drug transport by MsbA is assisted by apparent drug–proton antiport in a 
reaction that is driven by the inwardly directed DpH (interior alkaline) [56]. Interestingly, 
ethidium transport by this ABC transporter was also stimulated by a reversed Dy (interior 
positive in cells) rather than the physiological Dy (interior negative in cells). These findings 
indicate electrogenic n-ethidium+/H+ antiport in which n > 1 but, given the electrophysiological 
results obtained for LmrA (see below), could also indicate a more complex transport 
mechanism involving the translocation of additional ions. Proton coupling is associated with 
the MD dimer of MsbA as the antiport reaction is also observed for a truncated version of 
MsbA lacking the NBD (MsbA-MD). Furthermore, complete inhibition was observed by 
inactivating mutations in MsbA-MD (e.g. the triple mutant D41N-E149Q-D252N) [56]. As the 
MsbA-ATPase activity is stimulated by the DpH [56], ATP dependence and proton coupling 
must be integrated in a common transport reaction. Our findings for MsbA and MsbA-MD are 
reminiscent of previous studies on LmrA-MD which demonstrated apparent ethidium-proton 
symport [57]. Most recently, we have extended these studies to full-length LmrA in cells and 
proteoliposomes, and used electrophysiological studies on LmrA in planar lipid bilayers and 
giant unilamellar liposomes to characterise the stoichiometry of the ion transport reaction in 
detail [58]. The efflux of one ethidium+ and one H+ by LmrA occurs in symport with one Cl-, 
in counter-transport to two Na+, in an electrogenic reaction that is driven by the inwardly-
directed sodium motive force in cells (interior negative and low). Remarkably, the ion 
exchange reaction at the MDs is integrated in the catalytic cycle of nucleotide binding and 
hydrolysis by LmrA. The reaction is activated in the ATP-bound state of LmrA and is 
terminated in response to ATP hydrolysis. This type of regulation shares analogy to the ATP 
regulation of gating in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
ABC Cl- channel (also referred to as ABCC7) [59]. Although mutations in NBDs of LmrA and 
MsbA that inactivate ATP hydrolysis (e.g. deletion of lysine residue in Walker A in MsbA-
ΔK382 and LmrA-ΔK388) inactivate ethidium transport in metabolically-active cells [53, 56, 
58], both deletion mutants reconstituted in proteoliposomes are transport-active in the presence 
of appropriate electrochemical ion gradients. This suggests that, when nucleotide is present, 
nucleotide hydrolysis is compulsory for transport activity to prevent nucleotide trapping of 
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LmrA. These findings present ion coupling as a novel factor in the transport reaction for LmrA 
and MsbA. The ability to transport inorganic ions has also previously been observed for 
secondary-active multidrug transporters. Elegant studies with the E. coli MFS 
multidrug/proton antiporter MdfA demonstrated the ability of this system to mediate K+/H+ 
antiport and to confer alkali tolerance on the cell via MdfA-mediated proton import at the 
expense of the outwardly directed K+ gradient [60]. By analogy, the tetracycline efflux pumps 
Tet(L) and Tet(K) in Bacillus subtilis confer alkali tolerance by mediating (Na+)(K+)/H+ 
antiport as an alternative to tetracycline/H+ antiport [61]. Thus, even when antibiotics are 
absent, the selective pressure for the persistence of these multidrug transporters in bacterial 
cells might relate to their physiological roles in pHin regulation [62]. This conclusion could be 
relevant for any multidrug transporter with an additional physiological role beyond the 
transport of multiple drugs. 
 
Importance of NBDs in transport efficiency 
The ion motive force-dependence of ethidium transport by MsbA-MD and LmrA-MD raises 
important questions regarding the rationale behind the presence of NBDs in these ABC 
exporters. A systematic comparison of proton-coupled erythromycin transport by MsbA-MD 
versus ATP plus proton-coupled erythromycin transport by wildtype MsbA in a drug resistance 
assay demonstrated that the full-length protein is more efficient than the MD protein [56]. A 
similar conclusion was obtained in ethidium transport assays where wildtype MsbA effluxed 
ethidium against larger inwardly-directed concentration gradients than MsbA-MD. It is 
interesting to note that a dual mode of energy coupling has also been reported for other 
transporters; four examples will be discussed. (i) The arsenite and antimonite-translocating 
ArsB protein from E. coli [63, 64] acts as a secondary-active metalloid–proton antiporter, but 
when associated with the ArsA ATPase subunit also uses ATP to enhance its transport 
efficiency. This leads to higher levels of drug resistance as compared to the levels obtained 
with ArsB only. (ii) The SERCA Ca2+-ATPase sequesters Ca2+ in the sarcoplasmic reticulum 
of cardiac and skeletal muscle whereas the PMCA Ca2+-ATPase mediates Ca2+ extrusion across 
the plasma membrane of neurons. These P-type ATPases mediate Ca2+- proton antiport during 
the ATP-dependent transport reaction to ensure neutralization of the Ca2+-coordinating 
carboxylates following the dissociation of Ca2+ [65-67]. As the proton permeability of 
mammalian membranes is frequently too high to sustain significant chemical proton gradients, 
Ca2+ transport by these pumps is not known to be regulated by the DpH [65]. Thus, primary-
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active membrane transporters may translocate inorganic ions as part of their catalytic 
mechanisms, but the prevailing conditions determine whether (electro)chemical gradients for 
those ions are of a sufficient magnitude to affect the overall rate of transport. (iii) ATP and 
proton motive force-dependent transport are observed for protein secretion by the hetero-
trimeric membrane protein complex SecYEG in E. coli [68, 69]. In this system, phosphate bond 
energy is captured by the cytosolic motor protein SecA that uses ATP-driven cycles of insertion 
and retraction from the membrane-bound SecYEG translocon to mediate processive extrusion 
of preproteins through the cytoplasmic membrane. In vitro translocation assays show that the 
ATPase activity of SecA is required for the transmembrane transport of the NH2-terminus of 
the preprotein, which includes the signal sequence that targets proteins for export through the 
translocon. The ATPase activity of SecA is also required to drive the transport of downstream 
COOH-terminal segments of the preprotein in the absence of a Δp. However, once preprotein 
translocation is initiated, the translocation machinery can operate without the input of ATP in 
a reaction driven by the Δp via the auxiliary complex SecDF [70] and a recently proposed DpH-
dependent proton ratchet mechanism by SecYEG [71]. Similar to ArsAB and MsbA, the 
simultaneous input of ATP binding-hydrolysis and the Δp achieves efficient protein secretion. 
(iv) The type I secretion system HlyBD-TolC in E. coli contains the MsbA and LmrA 
homologue HlyB as the ABC translocator [72]. The extrusion of the secretion competent C-
terminal peptide (Actp) of the toxin protein haemolysin A by HlyBD-TolC was reported to be 
severely inhibited by the proton ionophore carbonylcyanide m-chlorophenylhydrazone 
(CCCP), which collapses simultaneously the Δy and ΔpH. Inhibition was also obtained by the 
addition of K+ plus valinomycin, a potassium ionophore that disrupts the Δy [73]. Thus, these 
data for HlyBD-TolC point to a transport mechanism that is ATP dependent as well as Δp 
dependent.  
 Our observations on the ATP and ion-coupling to multidrug transport by MsbA and 
LmrA might relate to roles of these ABC transporters in the transport of physically large or 
polymeric substrates via mechanisms that utilize a dual mode of energy coupling to obtain 
physiologically relevant translocation rates. For MsbA, one such substrate is core Lipid A. 
Structural studies with cryo-EM have shown the binding of Lipid A in the large chamber at the 
interface between the two MsbA half-transporters that form the transport-active complex [16]. 
However, as the pre-flopping conformation (containing Lipid A with head group near the 
cytoplasmic surface of the inner membrane) and post-flopping conformation (containing Lipid 
A with head group near the external surface of the inner membrane) show similar interactions 
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with ATP, it is not yet clear whether ATP is the sole form of metabolic energy that is relevant 
in Lipid A transport. In this context it is interesting to refer to recent progress on the mechanism 
of Ca2+-activated lipid scramblase TMEM16 proteins, which were found to contain a 
membrane-exposed hydrophilic groove that serves as a shared translocation pathway for lipids 
and ions [74, 75]. 
 
Outlook 
Multidrug transporters are fascinating molecular machines, many features of which remain to 
be discovered. In our studies on MsbA and LmrA, we uncovered novel mechanisms of 
inorganic ion transport in ABC exporters that are not yet predicted in current crystal and cryo-
EM structures, and that might be linked to physiological roles of these proteins in the transport 
of drugs, lipids or biopolymers, or be important in facilitating rate-limiting nucleotide-
independent steps in the overall transport reaction. Kinetic schemes for symport or antiport 
reactions by bacterial secondary-active transporters are usually relatively simple, and are 
thought to involve the binding and dissociation of transport substrates and H+ or Na+ as 
coupling ion. It is remarkable that kinetic schemes for mammalian secondary-active 
transporters are often far more complex. Take for example the mammalian excitatory amino 
acid transporters (EAAT), some of which mediate the re-uptake of synaptically released 
glutamate into nerve terminals. What started originally as a ‘simple’ glutamate - Na+ symporter 
mechanism based on biochemical assays [76] turned into a more complex co-transport 
mechanism of three Na+, one H+, and one glutamate, in counter-transport to one K+ when the 
transporter was studied by electrophysiological methods (reviewed in [77]). Moreover, EAAT 
transporters contain a Cl- channel that is thermodynamically uncoupled from glutamate uptake 
to ensure that the high rates of cation uptake in nerve terminals are not inhibited by the build-
up of a reversed Δy (interior positive) [78]. Traditionally, electrophysiological techniques have 
been applied to mammalian cells but not to bacteria, which were too small to be patched with 
glass pipettes. However, recent advances with the overexpression and detergent-based 
purification and reconstitution of bacterial membrane proteins has brought these transport 
systems within reach of electrophysiological techniques. Our electrophysiological and 
biochemical data for LmrA suggest that ion transport in bacterial transporters can have a similar 
complexity as observed for mammalian transporters. If the ABC Cl- channel CFTR (ABCC7) 
evolved from an ABC transporter through loss of function [59], it will certainly be interesting 
to test which mammalian ABC transporters translocate Cl- and/or other inorganic ions as part 
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of their transport activities. In conclusion, significant progress has been made in the structural 
biology of ABC multidrug transporters, but the proper interpretation of the structural data 
requires knowledge of all transport activities that are catalysed, as well as insight into the 
question of how these activities are coupled to metabolic energy. The synergy between 
structural, biochemical and biophysical studies on purified proteins in nanodiscs, 
proteoliposomes, giant unilamellar vesicles and planar lipid bilayers, and in vivo studies in 
intact cells therefore holds the promise to answering mechanistic questions regarding these 
membrane transporters and those in other families. 
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